At a glance
ClinicalIndex Comparison RecordN/ANot Yet Recruiting· 2,000 target
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China
In Brief
An observational study for Lung Cancer. Not yet recruiting, targeting 2,000 participants.
Detailed Summary
This is a multi-centre, observational study, with retrospective data collection and prospective active follow-up. The aim is to measure the treatment pattern and real-world outcomes of EGFR-TKI as an adjuvant therapy in patients with early-stage EGFR-mutated NSCLC. The study period ranges from July 1st, 2022 to June 30th, 2031. Approximately 2,000 patients will be enrolled from 15 sites in China.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
Countries--
Collaborators--
Timeline
N/ANot Yet Recruiting
20272028202920302031
First PostedMay 2026
Enrollment StartJun 2026
TodayJul 2026
Primary CompletionJun 2031
First PostedMay 18, 2026
Enrollment StartJun 30, 2026
Primary CompletionJun 30, 2031
TodayJul 1, 2026
Enrollment to primary: 5 yearsPosted 1 month agoPrimary completion in 5.0 years